Biopas

Biopas, founded in 2002 by Pascal and Maria Fernanda Forget, operates as a specialized Latin American pharmaceutical company headquartered in Bogota, Colombia. The company focuses on in-licensing, marketing, and selling specialty pharmaceutical products to address unmet medical needs in the region. Pascal Forget, the CEO, brings over 35 years of experience from roles at Schering-Plough, Grupo Farma, and Hoechst Roussel. Maria Fernanda Forget, the COO, has more than 25 years of experience with companies like Abbott, Grupo Farma, and Biogen. Their extensive backgrounds in the pharmaceutical industry have shaped Biopas's strategy.

The company's business model is designed to provide market access for cutting-edge, branded prescription products, explicitly excluding generics. It serves as a one-stop-shop for international biopharmaceutical firms looking to enter or expand their presence in Latin America, offering a turnkey solution that covers everything from regulatory approval to commercialization. This approach allows its partners, which include major pharmaceutical companies like UCB, Ferring, Ipsen, and Vertex, to navigate the complexities of the Latin American market with reduced disruption and cost. Biopas generates revenue through the marketing and sales of these in-licensed products.

Biopas operates through fully-owned subsidiaries in over 20 countries across Latin America, including key markets like Brazil, Mexico, Argentina, Colombia, and Chile. The company has established strong positions in several therapeutic areas, including Central Nervous System (CNS), Immunology, Rare Diseases, Oncology, Gastroenterology, and Dermatology. Its services encompass sales, marketing, medical support, market access, patient support programs, and pharmacovigilance, all adhering to international standards. A significant milestone for Biopas was its acquisition by the Swiss-based global commercial platform Swixx BioPharma in May 2024, a move aimed at creating a broad interregional platform. Following the acquisition, Biopas retains its name for Latin American operations, and its leadership team, including the founders, remains at the helm, with Pascal Forget also joining the Swixx BioPharma Board of Directors.

Keywords: specialty pharmaceuticals, Latin America pharma, in-licensing, pharmaceutical marketing, pharmaceutical sales, market access pharma, CNS therapeutics, immunology, rare diseases, oncology, gastroenterology, dermatology, biopharmaceutical commercialization, clinical trial support, regulatory affairs pharma, pharmaceutical distribution, turnkey pharma solutions, Bogota pharmaceuticals, Pascal Forget, Maria Fernanda Forget, Swixx BioPharma